Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you for your insight into this matter. I sent an email to Jeff this morning regarding this issue.
For non-accelerated filers like RespireRx the due date would be 45 days after the end of the quarter (so in RespireRx's case, May 15 to submit their 10-Q for the first quarter). Last year they submitted an NT-10Q at that time, and the 10-Q shortly thereafter. This year, for whatever reason, they did not submit either. Either way, RSPI is delinquent in submitting their filing for the first quarter of this year.
The due date for the second quarter filing will be August 15 (not July 31). I can say that with some confidence because their filings (or extensions) from previous years were filed on the dates that I've mentioned in this post.
The link said that annual filings were due 90 days after the end of the fiscal year for non-accelerated filers. The fiscal year ended Dec. 31, 2023. They filed an NT-10K on April 1st which would have extended the deadline by 15 days.
Are you able to set the record straight then? I don't know how the whole delinquency thing works.
I'd say the stock is primarily where it's at because of the age of the company (I've been following this company for close to 30 years since when it was known as Cortex Pharmaceuticals). It's been around for so long that eventually the market just assumed it would fade into oblivion like most pennies, and over time the share price dwindled. To the credit of management they've been able to advance some of their drug candidates to a point where excitement has begun to build again.
I would say that its present sub-penny status is largely due to the dilution of the past year, their delinquency in terms of filing, and the company's lackluster (to put it rather kindly) marketing to the investment community. But I'm hopeful these issues can be turned around and the company becomes a more shareholder friendly company, which, in conjunction with sustained good news, could result in a highly impressive run that could manage to hold onto its gains (IMHO).
Thanks very much for the post. EOM
$200.
$4000 today.
Ugly inside and out.
Someday this may go down as the worst call in the history of stocks. Already a terrible call but I'm here for it to get so much worse.
I was able to place Trans Trade on ignore without any difficulties.
Conversions at low prices are worse for shareholder equity and for attractiveness of the stock to potential investors, i.e., the lower the o/s the better. They surely cause more harm to the ROI of shareholders than conversions occurring in the midst of great news and sound regulatory compliance.
Alternatively, he can just be left alone to focus on the 10-K.
The website is indeed compete trash. The ResolutionRX.com.au website is okay so I'm hoping it's just a money thing and we'll get something that looks better before long.
All females going on niggor going forward.
That's right. But you could just Google market capitalization.
Called it.
Assuming they don't dilute this stock excessively this stock has legit $1.00+ potential easy. The non-opioid analgesic is the holy grail of pharmaceuticals in this day and age. Hopefully they don't spin off everything that is good. Long story short, yes you can flip this stock for a good trade, but I'm a LTBH. GLTY.
Email him yourself then.
My guess is it closes today at half a cent.
An order is oftentimes filled over the course of several trades.
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
Glen Rock, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that, as part of an ongoing collaboration, a scientist team led by Dr. David Fuller of the University of Florida has published a peer-reviewed research article describing the ability of CX1739, the Company’s lead clinical-stage AMPAkine (AMPA glutamate receptor potentiator), to restore bladder function in rodents that have undergone spinal cord injury (SCI).
Traumatic SCI often results in neurogenic bladder dysfunction that causes urological complications such as urinary infection, kidney damage and bladder cancer, reduces the quality of life and places patients with these injuries at increased risk of premature death. Restoration of bladder function is ranked as one of the highest priorities by individuals with SCI (Bourbeau et al., Spinal Cord 58 :1216–1226; 2020). Current treatment approaches usually require interventions such as catheterization for urinary voiding, which have their own set of risks and potentially significant set of complications. World-wide incidence rates rates range fron 12 to 59 cases per million depending on the country (Amidei et al., Spinal Cord 60 :812-819; 2022) and of these 70 - 84% showed neurogenic bladder dysfunction (Kumar et al., World Neurosurgery 113 :e345–e363; 2018).
The present paper, entitled “Acute ampakines increase voiding function and coordination in a rat model of SCI” (Rana, Alom et al . eLife 2023;12:RP89767. DOI: https://doi.org/10.7554/eLife.89767 ), convincingly demonstrates that in rats that had undergone contusion of the T9 spinal cord, CX1739 produced significant, dose dependent increases in the frequency of coordinated voiding and promoted coordinated external urethral sphincter electromyographic (EMG) activity. The placebo vehicle had no discernible impact on voiding.
Dr. Arnold Lippa, Interim President, Interim CEO and CSO of Respirex, commented that, “We are are very excited about this new data regarding CX1739 and its ability to improve bladder function in experimental animals that had undergone spinal injury. CX1739 has successfully completed multiple Phase 1 safety trials and Phase 2 proof of concept trials demonstrating target engagement.” He added that, “It has been a pleasure to work with Dr. Fuller, a long-time RespireRx collaborator, and his team of scientists. In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, he has demonstrated the ability of RespireRx’s lead AMPAkines to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI), including first respiration and now bladder functions. Depending on additional funding which we are seeking to raise, but cannot assure we will achieve, we have begun planning to conduct a translational, Phase 2 clinical study in SCI patients late this year. We believe that this research has the potential to represent a novel, breakthrough in the treatment of SCI, which is badly needed.”
About RespireRx Group
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units (“RespireRx Group”) are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABA A receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors.
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
AMPAkines . Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra ® (atomoxetine), and without the drawbacks of amphetamine-type stimulants. In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
GABAkines . Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has in-licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific, subset of GABA A receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant animal models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment-resistant epileptic patients who underwent surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
ResolutionRx: Pharmaceutical Cannabinoids.
ResolutionRx Ltd (Australian Company Number a/k/a ACN 664 925 651) was formed in Australia on January 11, 2023 by RespireRx as an unlisted public company. RespireRx has contributed by sublicense and license with ResolutionRx, its sleep apnea drug development program subject to certain liabilities. ResolutionRx will now engage in the research and development (“R&D”) associated with that program, initially for the development of a new formulation of dronabinol for use in a Phase 3 clinical trial and the filing of regulatory approval for the treatment of obstructive sleep apnea (“OSA”). The current total budget for that program over the next several years is approximately US$16.5 million, most, but not all of which is expected to be eligible for the Australian R&D Tax Incentive (“RDTI”). Dronabinol, an endocannabinoid receptor agonist, has already demonstrated significant improvement in the symptoms of OSA in two Phase 2 clinical trials. OSA is a serious respiratory disorder that impacts an estimated 90 million people in the United States, Australia, the United Kingdom and Germany and that has been linked to increased risk for hypertension, heart failure, depression, and diabetes. There are no approved drug treatments for OSA.
Because dronabinol is already FDA approved for the treatment of AIDS related anorexia and chemotherapy induced nausea and vomiting, RespireRx and ResolutionRx further believe that its repurposing strategy would only require, in the United States, approval by the FDA of a 505(b)(2) new drug application (“NDA”), an efficient regulatory pathway that allows the use of publicly available data.
Additional information about RespireRx and the matters discussed herein can be obtained on the RespireRx website at www.respirerx.com or RespireRx’s filings with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov . Additional information about ResolutionRx and the matters discussed herein can be obtained on the ResolutionRx website at https://www.resolutionrx.com.au .
Not a Securities Offering or Solicitation
This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sale of securities would be unlawful before registration or qualification under the laws of such jurisdiction.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Company intends that such forward-looking statements be subject to the safe harbor created thereby. These might include statements regarding the Company’s future plans, targets, estimates, assumptions, financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about research and development efforts, including, but not limited to, preclinical and clinical research design, execution, timing, costs and results, future product demand, supply, manufacturing, costs, marketing and pricing factors.
In some cases, forward-looking statements may be identified by words including “assumes,” “could,” “ongoing,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” “anticipates,” “believes,” “intends,” “estimates,” “expects,” “plans,” “contemplates,” “targets,” “continues,” “budgets,” “may,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words, and such statements may include, but are not limited to, statements regarding (i) future research plans, expenditures and results, (ii) potential collaborative arrangements, (iii) the potential utility of the Company’s product candidates, (iv) reorganization plans, and (v) the need for, and availability of, additional financing. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release.
These factors include but are not limited to, regulatory policies or changes thereto, available cash, research and development results, issuance of patents, competition from other similar businesses, interest of third parties in collaborations with us, and market and general economic factors, and other risk factors disclosed in “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC on April 17, 2023 (the “2022 Form 10-K”).
You should read these risk factors and the other cautionary statements made in the Company’s filings as being applicable to all related forward-looking statements wherever they appear in this press release. We cannot assure you that the forward-looking statements in this press release will prove to be accurate and therefore current and prospective investors, as well as current and potential collaborators and other current and potential stakeholders, are encouraged not to place undue reliance on forward-looking statements. You should read this press release completely. Other than as required by law, we undertake no obligation to update or revise these forward-looking statements, even though our situation may change in the future.
We caution current and prospective investors, as well as current and potential collaborators and other current and potential stakeholders, not to place undue reliance on any forward-looking statement that speaks only as of the date made and to recognize that forward-looking statements are predictions of future results, which may not occur as anticipated. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the risks and uncertainties described in the 2022 Form 10-K, in our quarterly reports on Form 10-Q, in our Current Reports on Form 8-K, and other reports that we file with or furnish to the SEC and in this press release, as well as others that we may consider immaterial or do not anticipate at this time. These forward-looking statements are based on assumptions regarding the Company’s business and technology, which involve judgments with respect to, among other things, future scientific, economic, regulatory and competitive conditions, collaborations with third parties, and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. Our expectations reflected in our forward-looking statements can be affected by inaccurate assumptions that we might make or by known or unknown risks and uncertainties, including those described in the 2022 Form 10-K, in our quarterly reports on Form 10-Q, in our Current Reports on Form 8-K, and other reports that we file with or furnish to the SEC and in this press release. These risks and uncertainties are not exclusive and further information concerning us and our business, including factors that potentially could materially affect our financial results or condition, may emerge from time to time. For more information about the risks and uncertainties the Company faces, see “Item 1A. Risk Factors” in our 2022 Form 10-K. Forward-looking statements speak only as of the date they are made. The Company does not undertake and specifically declines any obligation to update any forward-looking statements or to publicly announce the results of any revisions to any statements to reflect new information or future events or developments. We advise current and prospective investors, as well as current and potential collaborators and other current and potential stakeholders, to consult any further disclosures we may make on related subjects in our annual reports on Form 10-K and other reports that we file with or furnish to the SEC including but not limited to our most recent Form 10-Q as of September 30, 2023 filed with the SEC on November 17, 2023.
Company Contact:
Jeff Margolis
RespireRx Pharmaceuticals Inc.
126 Valley Road, Suite C
Glen Rock, NJ 07452
Senior Vice President, Chief Financial Officer, Treasurer and Secretary
Telephone: 917-834-7206
Email: jmargolis@respirerx.com
www.respirerx.com
Do you even English?
If they maxed out they'd probably ask for an increase by putting it to a vote.
The authorized is 2 billion. The shares outstanding on Feb. 13, 2024 was 660,665,615.
I found that at otcmarkets.com, RSPI quote, security details.
This comment is spot on, and especially true of anyone who says the name Clodfelter, IMHO.
You seem unintelligent.
All that did was prove that I have a right to take issue with him being called a doctor.
He isn't a doctor. You saw the following on Twitter and thought the MD stood for medical doctor.
Proactive USA
@proactive_NA
$RSPI RespireRX Pharmaceuticals announces Ponto Ventures’ MD Will Clodfelter will help drive business development https://tinyurl.com/yothpj2d @respirerxpharma #RSPI
It was me chasing the stock like a r-tard. Probably and by bad fortune someone else wanted to buy it at the same time and we competed with each other.
For me at least it wasn't based on any information or even a sound knowledge of the science. I just followed the stock casually since it was Cortex Pharm and I liked the SS. Of course after I bought it became a diluting pig.
This Will Clodfelter guy...
...has a LinkedIn profile where he's wearing a SUIT. 💯
P O N T O V E N T U R E S
O
N
T
O
V
E
N
T
U
R
E
S
From the RespireRx website:
Who is RespireRx’s Transfer Agent?
AST Financial LLC (f/k/a) American Stock Transfer and Trust Company
6201 15th Ave, Brooklyn, NY 11219
Tel: (800) 937-5449
---------------------------------------------
If the transfer agent isn't gagged I think you could just reach out to the transfer agent and ask. Google has their email as being help@astfinancial.com.
Dr. Lippa, Mr. Clodfelter*
The irony.
ResolutionRX.com.au website has been updated. Gone from the homepage is the futuristic marijuana plant partially obscured by some type of airborne particulate.
On mobile browsers (including Chrome and Safari) the line at the top of the homepage (which is new) that says Dronabinol for Obstructive Sleep Apnoea has the top half of the text cut off.
On the bright side, Dr. Lippa is no longer referred to as a Pd. D (he's a Ph.D, obviously).
The slide deck is new as well, in addition to other changes I noticed while taking a cursory glance.
GLTA...hopefully whoever is diluting stops and this thing can be a runner that doesn't come back down.
You branded him like a steer with that one. 🐄
The email of the Interim Chief Executive Officer is alippa@respirerx.com
Where I found it:
https://www.sec.gov/Archives/edgar/data/849636/000149315222006293/form253g2.htm
I've never tried emailing him.
I know the Senior VP and CFO is responsive:
jmargolis@respirerx.com